Clôture précédente | 106,23 |
Ouverture | 106,25 |
Offre | 0,00 x 1300 |
Vente | 0,00 x 800 |
Var. jour | 105,43 - 106,57 |
Sur 52 semaines | 99,14 - 119,65 |
Volume | |
Volume moyen | 7 219 438 |
Cap. boursière | 267,669B |
Bêta (mensuel sur 5 ans) | 0,35 |
Rapport P/E (sur 12 mois) | 58,68 |
BPA (sur 12 mois) | S.O. |
Date de bénéfices | S.O. |
Dividende et rendement à terme | 3,08 (2,92 %) |
Date ex-dividende | 14 déc. 2023 |
Objectif sur 1 an | S.O. |
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful